Recombinant Human CD27 Ligand/TNFSF7 Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CD27 ligand (CD27L), also named CD70, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7 (1, 2). Human CD27L cDNA encodes a 193 amino acid (aa) residue protein with a 17 aa N-terminal cytoplasmic domain, a 21 aa transmembrane domain and a 155 aa C-terminal extracellular domain. Human and mouse CD27L share approximated 56% aa sequence identity. CD27L is expected to exist as non-covalent homotrimers. CD70 is constitutively expressed on medullary thymic epithelial cells (mTECs) in human and mouse and on certain unconventional APCs in the mouse intestine (3). CD70 is also exclusively expressed on DCs (5), B cells (5), conventional- and regulatory T cells (6) and NK cells (7) but only after their activation. CD70 expression is highly regulated by antigen through Pattern Recognition Receptors (PRRs), T cell and B cell antigen receptors (8), and further tuned by cytokines such as IL-1 alpha ,
IL-12, TNF alpha , prostaglandin E2 and by CD28 and CD40 co-stimulation (9).  Ligation of CD27 on T cells provides co-stimulatory signals and promotes T cell proliferation, antigen-specific CD4⁺ and CD8⁺ T cells clonal expansion, effector & memory T-cell differentiation, and effector T-cell survival & T-cell memory formation (10-12). Ligation of CD27 on mouse B cell and NK cells promotes the B- and NK-cell response by supporting B-cell expansion in the germinal center and increasing IFN-gamma levels in NK cells, in turn enhancing NK cytotoxic capability, which can contribute to tumor control (13,14). Overall, CD27/CD70 co-stimulatory system promote T, B and NK cell responses and particularly the CTL response, and is a target in cancer immunotherapy (15).

Array 9328-CL

• CD27 Ligand/TNFSF7/CD70 Antibodies
• CD27 Ligand/TNFSF7/CD70 Lysate
• CD27 Ligand/TNFSF7/CD70 ELISA
• CD27 Ligand/TNFSF7/CD70 Proteins and Enzymes